Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor - Wikidata - awgldk - TriplyDB

Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor

Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor

http://www.wikidata.org/entity/Q28258969

about

New developments in atherosclerosis: clinical potential of PCSK9 inhibition Current therapies for lowering lipoprotein (a)The year in cardiology 2015: prevention PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era PCSK9 inhibitors - mechanisms of action Lipoprotein (a)-We Know So Much Yet Still Have Much to Learn …The Effects of Tamoxifen on Plasma Lipoprotein(a) Concentrations: Systematic Review and Meta-Analysis.Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering.Mechanistic insights into Lp(a)-induced IL-8 expression: a role for oxidized phospholipid modification of apo(a).Urine-sample-derived human induced pluripotent stem cells as a model to study PCSK9-mediated autosomal dominant hypercholesterolemia.Distinct metabolism of apolipoproteins (a) and B-100 within plasma lipoprotein(a).PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role.PCSK9 Association With Lipoprotein(a)Recurrent Embolic Strokes of Undetermined Source in a Patient with Extreme Lipoprotein(a) Levels Correlation between serum levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) and atherogenic lipoproteins in patients with coronary artery disease Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans.Lipoprotein(a) and inhibitors of proprotein convertase subtilisin/kexin type 9.Evolocumab in the treatment of dyslipidemia: pre-clinical and clinical pharmacology.Pathobiology of Lp(a) in calcific aortic valve disease.An evaluation of alirocumab for the treatment of hypercholesterolemia.Evolocumab: A Review in Hyperlipidemia.Characterization of the I4399M variant of apolipoprotein(a): implications for altered prothrombotic properties of lipoprotein(a).Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism.Proprotein convertase subtilisin / kexin 9 (PCSK9) inhibitors and the future of dyslipidemia therapy: an updated patent review (2011-2015).Emerging Therapeutic Options for Lowering of Lipoprotein(a): Implications for Prevention of Cardiovascular Disease.Lipoprotein (a): a historical appraisal.The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9.Lipoprotein(a): A missing culprit in the management of athero-thrombosis?Hepatitis C virus and proprotein convertase subtilisin/kexin type 9: a detrimental interaction to increase viral infectivity and disrupt lipid metabolism.Proprotein convertase subtilisin/kexin type 9 levels and aortic valve calcification: A prospective, cross sectional study Treatment-Induced Viral Cure of Hepatitis C Virus-Infected Patients Involves a Dynamic Interplay among three Important Molecular Players in Lipid Homeostasis: Circulating microRNA (miR)-24, miR-223, and Proprotein Convertase Subtilisin/Kexin Type 9.Apolipoprotein(a) inhibits hepatitis C virus entry through interaction with infectious particles.Lipoprotein(a) concentrations, apolipoprotein(a) isoforms and clinical endpoints in haemodialysis patients with type 2 diabetes mellitus: results from the 4D Study.Evidence-based assessment of lipoprotein(a) as a risk biomarker for cardiovascular diseases - Some answers and still many questions.Analysis of the association between plasma PCSK9 and Lp(a) in Han Chinese.Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin/kexin type 9.The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol.HDL-C, ABCA1-mediated cholesterol efflux, and lipoprotein(a): insights into a potential novel physiologic role of lipoprotein(a).A phase 1 study to evaluate the safety and LDL cholesterol-lowering effects of RG7652, a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9.Novel Lipoprotein(a) Catabolism Pathway via Apolipoprotein(a) Recycling: Adding the Plasminogen Receptor PlgRKT to the List.

P2860

Q26783407-4EBB5F37-C9A9-4A17-AFFC-1AE9E5459B8A Q26830297-F47B75F8-821B-4819-96B4-C24820688CBB Q28072221-F274439D-0DD0-403D-ADF4-D98A16105949 Q28073656-D33AD0FB-CE0F-4D82-AC3B-A4FE21F617C2 Q28073987-4F7AA2D4-D855-4F9D-B473-112B215FF3D1 Q28275137-F517433A-4B21-42C6-8089-8F54BA015CC4 Q30234123-F9E2CA04-8F94-48AB-8DCF-0DE5B78E70CE Q34536594-192FC99B-3292-4750-80FC-F46AB84FC8F1 Q36307282-007E9427-D607-4ADD-BF67-26B7E014FF95 Q36506609-25E6F7B5-1042-4F57-ADFD-2EBD9D6ED925 Q36696683-25CC60BF-F841-47D5-9B1E-02ED7F30AD9E Q36930207-69BD9A99-5AB7-4232-96AE-5C4C0E6CCA56 Q37037349-089AAC2C-D5A4-4E2B-A3C9-9137A811977D Q37218193-ECA81EB9-7309-498C-9558-D1A73555E1B9 Q37278608-3CFF37BA-6B0F-4644-B28D-68924DD93E67 Q37603961-E5F5C864-BF49-425B-8643-DB09575C985C Q37636912-0F81422E-692D-400B-AD79-28E35D2DE61E Q38570558-0092F580-2937-4127-B6EF-01D68A66B6BF Q38620736-77E66862-4387-4872-9E8A-3B63C96D291F Q38632198-BFBEAF19-F674-4FF5-ABAE-E3EFC91C4A79 Q38661399-38DB61FD-98F7-4EB1-9850-4A59B7C7A8FF Q38717170-50E5EEC8-B6DC-49F2-A030-D62D992C7698 Q38839105-355E6AFA-60FF-4548-AB26-3F550B680575 Q38846832-6C269DA5-BB68-4831-9C23-1147CBF65DAA Q38985774-483E51A8-B1F6-427B-A57F-B34DF6B7FB6B Q39002143-A3FD0F85-7853-41BD-9071-D1FF3614CDB9 Q39030028-66767D95-2713-4D39-A973-6148D0B0F954 Q39368804-4C80109B-608E-4137-8076-9006F38A66BB Q39443793-326D6D74-B820-4B85-89BB-AAC5BEC5BCEF Q39698712-140C4C43-75FA-436B-8EAE-9BCE56447DF7 Q40061048-BE7A8824-0129-4CF0-90A9-597381765E54 Q40348492-E5C0CB32-B603-4748-92B3-ABFF61CEFEF2 Q40469545-AAF37883-418D-45FD-9B9A-6700CC49844E Q40757066-29E66E8C-AAFD-4BCF-A6D5-BA51187A24B7 Q40899815-1EEC7081-0588-4074-AA04-C53B3091BE5B Q41153491-21CBA080-63F8-4B5C-8C56-82935D39698A Q42367561-279E27A4-974E-4270-A189-84B4E701BD1D Q42408461-364284E1-5AB8-4A60-A1AE-01E326B03438 Q46015940-BCD0959B-07F0-432D-B098-3C2E1B1A2271 Q46066892-4AA7EC25-7DAB-4B9E-B5C5-08DCF7D6C630

P2860

Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor

http://www.wikidata.org/entity/Q28258969

description

2015 nî lūn-bûn

@nan

2015 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Lipoprotein(a) catabolism is r ...... w density lipoprotein receptor

@ast

Lipoprotein(a) catabolism is r ...... w density lipoprotein receptor

@en

Lipoprotein(a) catabolism is r ...... w density lipoprotein receptor

@nl

type

label

Lipoprotein(a) catabolism is r ...... w density lipoprotein receptor

@ast

Lipoprotein(a) catabolism is r ...... w density lipoprotein receptor

@en

Lipoprotein(a) catabolism is r ...... w density lipoprotein receptor

@nl

prefLabel

Lipoprotein(a) catabolism is r ...... w density lipoprotein receptor

@ast

Lipoprotein(a) catabolism is r ...... w density lipoprotein receptor

@en

Lipoprotein(a) catabolism is r ...... w density lipoprotein receptor

@nl

P1433

Q28258969-7424876E-D611-4270-AB8A-92CC7E053C05

P1476

Q28258969-6352B6E5-5910-44A8-B82C-9D3782A1FBDD

P2093

Q28258969-376552F4-C2FA-48E0-B8F8-23147A06844D

Q28258969-37BFCD20-DECF-488B-8712-50C1BC8FB3CF

Q28258969-AB27324C-B270-4EEB-B814-64664DD1F313

P2860

Q28258969-043A678D-14CB-4875-823B-4995959E6A14

Q28258969-08F03E0F-00A8-43AD-B88E-F819D1C17B30

Q28258969-091BEBFB-77B7-4759-92C0-C01C87AE7DC9

Q28258969-0D216A83-008A-4C7B-8539-0565119D94AF

Q28258969-11E4F8F5-3DFC-45FF-A0BC-F51512AF35FA

Q28258969-1301ACDD-23B0-4182-BFCC-A6ADF1533679

Q28258969-147FABA4-342A-44DF-9E4E-2C81E2B41DA7

Q28258969-1664A1E1-2E6B-4973-98B9-9AE747331FBC

Q28258969-18EF9614-3F91-46D6-8E83-6D823A3A07DF

Q28258969-19E0FC86-A539-4285-BAE8-D14BCB10AFE7

P304

Q28258969-F947575C-A036-4522-AA5E-B70A6C666AEA

P31

Q28258969-43D0257C-0132-4C97-9555-07BB4E4E1DCD

P3181

Q28258969-280F341F-FB5E-4B3A-B527-9D1D64B795C9

P356

Q28258969-A2BE3C5D-40A3-4098-8305-F0F48C1FAB4E

P407

Q28258969-F56AA7D0-C541-4B79-B59A-2E21358F4046

P433

Q28258969-873DCB04-A2C2-4937-9DFC-7B2268CCFBA5

P478

Q28258969-569F1855-D7DB-4D9D-B3EF-5AEA0561FB24

P50

Q28258969-5DB9F2E5-FE38-443E-A710-54CC2F296589

Q28258969-A929D7D3-926C-4248-A149-531C17062F03

Q28258969-D461B9A5-06E6-44BF-B83C-CFAAD2D8DB28

P577

Q28258969-9CE6C9DA-507F-40A0-B312-0BEADC3B31A6

P5875

Q28258969-3351A1FC-705F-4594-8D20-7CA6684F5CDD

P698

Q28258969-621919CF-0062-4703-A126-BF68435B89F7

P921

Q28258969-249CA395-F2DD-4585-A65A-A5434F385EA2

Q28258969-6C79FAAC-7784-43F4-B4EA-678992DFF274

Q28258969-BF2E71AB-2402-4045-845A-2ED8BAD96AB9

P932

Q28258969-057C93D4-3B18-4F43-8D6B-F75B9CAC8F34

P3181

P356

JBC.M114.611988

P1433

Journal of Biological Chemistry

P1476

Lipoprotein(a) catabolism is r ...... w density lipoprotein receptor

@en

P2093

Marlys L Koschinsky

http://www.w3.org/2001/XMLSchema#string

Rocco Romagnuolo

http://www.w3.org/2001/XMLSchema#string

Santica M Marcovina

http://www.w3.org/2001/XMLSchema#string

P2860

The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation

The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2

Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation

The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR

ARH is a modular adaptor protein that interacts with the LDL receptor, clathrin, and AP-2

Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice

L-trans-Epoxysuccinyl-leucylamido(4-guanidino)butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins B, H and L

The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans

Inducible inactivation of hepatic LRP gene by cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants

Molecular basis for LDL receptor recognition by PCSK9

P304

11649-62

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2126291

http://www.w3.org/2001/XMLSchema#string

P356

10.1074/JBC.M114.611988

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

290

http://www.w3.org/2001/XMLSchema#string

P50

Michael B. Boffa

P577

2015-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

273961152

http://www.w3.org/2001/XMLSchema#string

P698

25778403

http://www.w3.org/2001/XMLSchema#string

P921

P932

4416867

http://www.w3.org/2001/XMLSchema#string